Virginia Commonwealth University

  • CTSA Program Hub
    Virginia Commonwealth University
  • Consortium News
    headshot of Albhaisi over image of test tubes being labelled
    VCU Wright Center helps fund and build a biobank to fight COVID-19
  • Consortium News
    headshot of Steven Woolf
    VCU Wright Center researcher publishes COVID-19 excess mortality data
  • Consortium News
    screenshot of Dr. Winn's town hall
    VCU Wright Center hosting series of town halls for VSU undergrads
  • Educational Content
    image of puzzle with DNA strand
    Post-baccalaureate Certificate in Clinical Research
    Virginia Commonwealth University
  • Consortium News
    research/lab graphic
    VCU Wright Center continues to lead COVID-19 trials activation
  • Consortium News
    image of puzzle with DNA strand
    VCU Wright Center launches Virginia’s first certificate program to train future clinical research professionals
  • Consortium News
    headshots of Van Tassell and Abbate
    "Calming the Storm": VCU Wright Center researchers talk about inflammation and COVID-19
  • Consortium News
    photo of Kathy White
    Patient in VCU Wright Center COVID trial shares her story for Clinical Trials Day
  • Event
    graphic with series information
    Intro to Genomic Databases with VCU Wright Center
  • Consortium News
    aerial of VCU commons
    VCU Wright Center helps fund 11 more COVID-19 research projects
  • Consortium News
    photo of Julian Zhu in lab
    VCU Wright Center scholar developing vaccine patch
  • Consortium News
    aeiral shot of VCU medical campus
    VCU Wright Center joins initiative to share faculty expertise, inventions to spur fight against COVID-19
  • To compare the effect of hydroxychloroquine versus placebo on clinical outcomes, measured using the COVID Ordinal Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization.

    To compare the effect of hydroxychloroquine versus placebo on clinical outcomes
    Target Population
    Adults with COVID-19 requiring hospitalization.
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 3
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    35
    CTSA Support
    Not Sure
    Locations
    Multi-site - 43 locations
  • Multicenter industry sponsored clinical trial exploring canakinumab, IL-1beta antibody, for the prevention of death and worsening respiratory failure in patients with COVID-19 pneumonia and hyper-inflammation.

    Does IL-1beta contribute to respiratory failure in COVID-19 pneumonia?
    Target Population
    Severe COVID19 - non intubated
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 3
    Clinical Trial Network Utilization
    No
    Accrual Target Number
    450
    CTSA Support
    Yes
    Locations
    Multicenter clinical trial, VCU as one of the sites Within VCU (MCV-Richmond, VA, and CMH-South Hill, VA)
  • The purpose of this study is to provide Remdesivir (RDV) to participants with severe COVID-19. The primary objective of this study is to evaluate the efficacy of 2 RDV regimens with respect to the normalization of temperature and oxygen saturation through Day 14. The secondary objective of this study is to evaluate the safety and tolerability of RDV.

    The primary objective of this study is to evaluate the efficacy of 2 RDV regimens with respect to the normalization of temperature and oxygen saturation through Day 14. The secondary objective of this study is to evaluate the safety and tolerability of RDV.
    Target Population
    Severe COVID-19
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 3
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    5
    CTSA Support
    Not Sure
    Locations
    Multi-Site - 182 locations
  • The purpose of this study is to provide Remdesivir (RDV) to participants with COVID-19. The primary objective is to evaluate the efficacy of 2 RDV regimens compared to standard of care (SOC), with respect to the proportion of participants discharged on or before Day 14. The secondary objective of this study is to evaluate the safety and tolerability of RDV compared to SOC.

    The primary objective is to evaluate the efficacy of 2 RDV regimens compared to standard of care (SOC), with respect to the proportion of participants discharged on or before Day 14. The secondary objective of this study is to evaluate the safety and tolerability of RDV compared to SOC.
    Target Population
    Moderate COVID19 (hospitalized)
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 3
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    1600
    CTSA Support
    Not Sure
    Locations
    Multi-site: 183 locations
  • CM4620-IE, a calcium release-activated calcium (CRAC) channel inhibitor, potently blocks the production and release of pro-inflammatory cytokines from immune cells, including those elevated by SARS-CoV-2 infection (e.g., IL-6, IL-17 and TNF-α) and may interrupt the cascade of events leading to acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) in patients with severe COVID-19 pneumonia. It may further directly protect the lung through a local effect on CRAC channels and modulation of NFAT-induced activation of the lung endothelium. Recently published literature showed that a CRAC channel inhibitor similar to CM4620 was beneficial in animal models of lung injury by both a direct effect on pulmonary endothelial cells, as well as a systemic effect on CRAC channels of immune cells. Lending further support are in vivo efficacy data on lung IL-6, TNFα, and MPO mRNA production in animals with experimental acute pancreatitis, a known cause of ALI/ARDS treated with CM4620-IE and data from a 2a study of CM4620-IE in patients with acute pancreatitis and accompanying SIRS with hypoxemia at presentation that showed both a reduction in significantly elevated IL-6 levels and improved oxygenation in patients treated with CM4620-IE.

    CM4620-IE will be administered intravenously as a continuous infusion over 4 hours via a bag and tubing compatible with lipid emulsions and using a 1.2-micron filter.
    Target Population
    Severe COVID19
    Primary Investigator
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 2
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    30
    CTSA Support
    Not Sure
    Locations
  • Primary Objectives: Phase 2: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe COVID-19. Phase 3: The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.

    The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with severe or critical COVID-19.
    Target Population
    ICU - Severe COVID19
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Submitted to clinicaltrials.gov
    Current Study Status
    Recruiting
    Current Study Phase
    Phase 2
    Clinical Trial Network Utilization
    Not Sure
    Accrual Target Number
    400
    CTSA Support
    Not Sure
    Locations
    Multi-site - 63 locations
  • Phase II clinical trial of GM-CSF-receptor antibody or placebo in patients with COVID-19 pneumonia and hyper-inflammation

    The study hypothesis is that early treatment with mavrilumumab can reduce fever and prevent progression to severe respiratory failure and death in patients with severe COVID-19 pneumonia and clinical and biological features of hyperinflammation.
    Target Population
    Severe COVID-19 Pneumonia and Systemic Hyper-inflammation
    Primary Investigator
    Contact Email
    Sponsor
    Study Type
    Treatments and Interventions
    Clinicaltrials.gov Status
    Pre-clinicaltrials.gov
    Current Study Status
    Not yet recruiting
    Current Study Phase
    Phase 2
    Clinical Trial Network Utilization
    No
    Accrual Target Number
    60
    CTSA Support
    Yes
  • Consortium News
    stock image of needle and drug
    VCU Wright Center brings canakinumab trials in fight against COVID-19
  • Consortium News
    photo of Dr. Arun Sanyal in front of the hospital
    VCU Wright Researcher Profiled in Magazine Article about Clinical Trials
  • Consortium News
    graphic of clipboard and checklist
    VCU Wright Center Director Promotes Community Engagement
  • Consortium News
    aerial view of VCU medical campus
    VCU Wright Center Helps Fund 20 COVID-19 Projects
  • Consortium News
    stock image of needle and drug
    VCU Wright Center Researchers Open New COVID-19 Drug Treatment Trial
  • Consortium News
    Drs. Abbate, Sanyal, and de Wit in masks outside VCU hospital
    VCU Wright Center Researchers Featured in Story about Clinical Trials
  • Consortium News
    doctor looking at brain scans
    Brain Study Using VCU Wright Center Research MRI Renewed
  • Consortium News
    racks of N95 masks hung around a machine, being sterilized
    VCU Wright Center Researchers Develop N95 Mask Sterilization Program
  • Consortium News
    Laboratory work stock image
    VCU Wright Center Director Answers Questions about Clinical Trials for a General Audience
  • Consortium News
    VCU ER doctor holds ventilator device he created.
    VCU Wright Center Facilitates 3D Printed Ventilator Project